<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00663481</url>
  </required_header>
  <id_info>
    <org_study_id>CoFactor 510-20</org_study_id>
    <nct_id>NCT00663481</nct_id>
  </id_info>
  <brief_title>A Clinical Trial of CoFactor Formulations and Leucovorin Administered Intravenously in Healthy, Adult Subjects.</brief_title>
  <official_title>A Single Dose, Within Subject, 3 Period, Pharmacokinetic Bridging Study of CoFactor Formulations and of Leucovorin Administered Intravenously in Healthy, Adult Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mast Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mast Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and tolerability of CoFactor in healthy&#xD;
      subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic profile of CoFactor formulations in healthy adult subjects.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To measure the 5,10 methylenetetrahydrofolic acid levels after CoFactor and leucovorin administration</measure>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Healthy Adults</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CoFactor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CoFactor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Leucovorin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CoFactor</intervention_name>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>ANX-510</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and Females age 18-65 inclusive at screening.&#xD;
&#xD;
          -  Subject has to agree to practice abstinence or medically accepted contraception and&#xD;
             not to participate in sperm donation or in vitro fertilization.&#xD;
&#xD;
          -  Body Mass Index in the range of 18 to 30 kg/m2 and body weight of 45 to 95 kg.&#xD;
&#xD;
          -  Subject must be healthy as determined by the investigator on the basis of screening&#xD;
             evaluations.&#xD;
&#xD;
          -  Subject must be nonsmoker or smoker of fewer than 10 cigarettes per day as determined&#xD;
             by history. Must be able to abstain from smoking during the in-clinic stay.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of clinically significant illness within 21 days prior to dosing, viral or&#xD;
             bacterial infection, or documented drug allergies that may affect subject's safety&#xD;
             during the study.&#xD;
&#xD;
          -  Laboratory or clinical evidence suggestive of disease.&#xD;
&#xD;
          -  Clinically significant or predisposing disorder that may interfere with the&#xD;
             absorption, distribution, metabolism and/or excretion of drugs.&#xD;
&#xD;
          -  History of drug abuse within 1 year of dosing and/or admitted alcohol abuse or history&#xD;
             of alcohol use that may interfere with the ability to comply.&#xD;
&#xD;
          -  Pregnant, lactating, or positive pregnancy test.&#xD;
&#xD;
          -  Clinically significant electrocardiogram abnormalities.&#xD;
&#xD;
          -  History of positive test for hepatitis B or C, or HIV.&#xD;
&#xD;
          -  Positive findings of urine narcotic screen.&#xD;
&#xD;
          -  History of drug allergy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald Goldwater, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Parexel International - Baltimore CPRU</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Parexel International - Baltimore CPRU</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2009</verification_date>
  <study_first_submitted>April 18, 2008</study_first_submitted>
  <study_first_submitted_qc>April 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2008</study_first_posted>
  <last_update_submitted>May 27, 2009</last_update_submitted>
  <last_update_submitted_qc>May 27, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2009</last_update_posted>
  <responsible_party>
    <name_title>Jeff Stewart, MBA</name_title>
    <organization>ADVENTRX Pharmaceuticals, Inc.</organization>
  </responsible_party>
  <keyword>CoFactor</keyword>
  <keyword>ANX-510</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

